On August 27, 2015, the U.S. Department of Health and Human Services released the long-awaited and much-anticipated proposed 340B Drug Pricing Program Omnibus Guidance. This On the Subject highlights key takeaways from the guidance (including the significant revisions to the definitions of drugs eligible for discounted 340B pricing and patients eligible to receive such discounted drugs) and provides an outline of its provisions. McDermott will host a webinar in the near future to further discuss the proposed guidance and its ramifications; more details will be released shortly.